##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---

FORM 10-Q



---



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

For the Quarterly Period Ended September 30, 2006

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934
|- | -----------------------------------------------------------------------------

For the Transition Period from              to

Commission file number 0-21371



---

APPLIED IMAGING CORP.

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 77-0120490                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)



|                                         |  |           
|---------------------------------------- |  | ----------
|120 Baytech DriveSan Jose, California    |  | 95134-2302
|(Address of principal executive offices) |  | (Zip Code)

(408) 719-6400

(Registrants telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report).



---

Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days.    x  Yes ̈No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a
non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

 ̈Large accelerated filer ̈Accelerated filer    x  Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ̈Yes    x  No

The number of shares of Common Stock, with $0.001 par
value, outstanding on October 31, 2006 was 5,588,593.



---



---

##### Table of Contents

APPLIED IMAGING CORP.

INDEX



|          |  |                                                                                                                 |  |      
|--------- |  | --------------------------------------------------------------------------------------------------------------- |  | -----
|          |  |                                                                                                                 |  | Page 
|          |  | PART I. FINANCIAL INFORMATION                                                                                   |  |      
|          |  |                                                                                                                
|Item 1.   |  | Financial Statements (Unaudited)                                                                                |  | 3    
|          |  |                                                                                                                
|          |  | Condensed Consolidated Balance Sheets as of September 30, 2006 and December 31, 2005                            |  | 4    
|          |  |                                                                                                                
|          |  | Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2006 and 2005 |  | 5    
|          |  |                                                                                                                
|          |  | Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2006 and 2005           |  | 6    
|          |  |                                                                                                                
|          |  | Notes to Condensed Consolidated Financial Statements                                                            |  | 7-15 
|          |  |                                                                                                                
|Item 2.   |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                           |  | 16-20
|          |  |                                                                                                                
|Item 3.   |  | Quantitative and Qualitative Disclosures about Market Risk Derivatives and Financial Instruments                |  | 20   
|          |  |                                                                                                                
|Item 4.   |  | Controls and Procedures                                                                                         |  | 21   
|          |  |                                                                                                                
|          |  | PART II. OTHER INFORMATION                                                                                      |  |      
|          |  |                                                                                                                
|Item 1.   |  | Legal Proceedings                                                                                               |  | 21   
|          |  |                                                                                                                
|Item 1. a |  | Risk Factors                                                                                                    |  | 21-29
|          |  |                                                                                                                
|Item 2.   |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                     |  | 29   
|          |  |                                                                                                                
|Item 3.   |  | Defaults Upon Senior Securities                                                                                 |  | 29   
|          |  |                                                                                                                
|Item 4.   |  | Submission of Matters to a Vote of Security Holders                                                             |  | 29   
|          |  |                                                                                                                
|Item 5.   |  | Other Information                                                                                               |  | 29   
|          |  |                                                                                                                
|Item 6.   |  | Exhibits                                                                                                        |  | 29   
|          |  |                                                                                                                
|          |  | Signature                                                                                                       |  | 31   



2



---

##### Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Unless the context otherwise indicates, all share and per share common stock
information in this Quarterly Report reflects a 1-for-4 reverse stock split of the common stock effective May 20, 2005.



3



---

##### Table of Contents

APPLIED IMAGING CORP. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited, in thousands except par values)



|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ----------------- | ------- | - | ---------------- | - | ------- | -
|                                                                                                                                                                       |  | September 30,2006 |         |   | December 31,2005 |  
|ASSETS                                                                                                                                                                 |  |                   |         |   |                  |   |         |  
|Current assets:                                                                                                                                                        |  |                   |         |   |                  |   |         |  
|Cash and cash equivalents                                                                                                                                              |  | $                 | 3,355   |   |                  | $ | 3,136   |  
|Restricted cash                                                                                                                                                        |  |                   | 168     |   |                  |   | 172     |  
|Trade accounts receivable, net of allowance for doubtful accounts                                                                                                      |  |                   | 4,684   |   |                  |   | 4,806   |  
|Inventories                                                                                                                                                            |  |                   | 260     |   |                  |   | 434     |  
|Prepaid expenses and other current assets                                                                                                                              |  |                   | 348     |   |                  |   | 354     |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total current assets                                                                                                                                                   |  |                   | 8,815   |   |                  |   | 8,902   |  
|Property and equipment, net                                                                                                                                            |  |                   | 1,111   |   |                  |   | 1,208   |  
|Goodwill                                                                                                                                                               |  |                   | 2,364   |   |                  |   | 2,364   |  
|Other assets                                                                                                                                                           |  |                   | 49      |   |                  |   | 54      |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total assets                                                                                                                                                           |  | $                 | 12,339  |   |                  | $ | 12,528  |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                                                                                   |  |                   |         |   |                  |   |         |  
|Current liabilities:                                                                                                                                                   |  |                   |         |   |                  |   |         |  
|Bank debt                                                                                                                                                              |  | $                 | 641     |   |                  | $ | 2,054   |  
|Accounts payable                                                                                                                                                       |  |                   | 1,908   |   |                  |   | 1,288   |  
|Accrued expenses                                                                                                                                                       |  |                   | 2,725   |   |                  |   | 2,368   |  
|Deferred rent, current                                                                                                                                                 |  |                   | 153     |   |                  |   | 149     |  
|Deferred revenue, current                                                                                                                                              |  |                   | 2,945   |   |                  |   | 3,537   |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total current liabilities                                                                                                                                              |  |                   | 8,372   |   |                  |   | 9,396   |  
|Deferred rent, non-current                                                                                                                                             |  |                   | 301     |   |                  |   | 374     |  
|Deferred revenue, non-current                                                                                                                                          |  |                   | 455     |   |                  |   | 405     |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total liabilities                                                                                                                                                      |  |                   | 9,128   |   |                  |   | 10,175  |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Commitments and contingencies (Note 3)                                                                                                                                 |  |                   |         |   |                  |   |         |  
|Stockholders equity:                                                                                                                                                  |  |                   |         |   |                  |   |         |  
|Preferred stock, $0.001 par value; 6,000,000 shares authorized; none issued and outstanding at September 30, 2006 and December 31,
2005                                |  |                   |        |   |                  |   |        |  
|Common stock; $0.001 par value; 50,000,000 shares authorized; 5,588,593 and 4,814,781 issued and outstanding at September 30, 2006 and
December 31, 2005, respectively |  |                   | 19      |   |                  |   | 19      |  
|Additional paid-in capital                                                                                                                                             |  |                   | 54,526  |   |                  |   | 53,021  |  
|Accumulated deficit                                                                                                                                                    |  |                   | (50,967 | ) |                  |   | (50,320 | )
|Accumulated other comprehensive loss                                                                                                                                   |  |                   | (367    | ) |                  |   | (367    | )
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total stockholders equity                                                                                                                                             |  |                   | 3,211   |   |                  |   | 2,353   |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  
|Total liabilities and stockholders equity                                                                                                                             |  | $                 | 12,339  |   |                  | $ | 12,528  |  
|                                                                                                                                                                       |  |                   |         |   |                  |   |         |  

The accompanying notes are an integral part of these unaudited condensed consolidated financial
statements.



4



---

##### Table of Contents

APPLIED IMAGING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except per share data)



|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|----------------------------------------------------------------------------- |  | ------------------------------- | ----- | - | ------------------------------ | - | ----- | ---- |  | - | ------ | - |  | - | ------ | -
|                                                                              |  | Three Months EndedSeptember 30, |       |   | Nine Months EndedSeptember 30, |  
|                                                                              |  | 2006                            |       |   | 2005                           |   |       | 2006 |  |   | 2005   |  
|Revenues                                                                      |  | $                               | 5,091 |   |                                | $ | 4,933 |      |  | $ | 14,989 |   |  | $ | 14,735 |  
|Cost of revenues(a)                                                           |  |                                 | 1,867 |   |                                |   | 1,746 |      |  |   | 5,504  |   |  |   | 5,785  |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Gross profit                                                                  |  |                                 | 3,224 |   |                                |   | 3,187 |      |  |   | 9,485  |   |  |   | 8,950  |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Operating expenses                                                            |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Research and development(a)                                                   |  |                                 | 641   |   |                                |   | 800   |      |  |   | 2,142  |   |  |   | 2,555  |  
|Sales and marketing(a)                                                        |  |                                 | 1,376 |   |                                |   | 1,393 |      |  |   | 4,282  |   |  |   | 4,115  |  
|General and administrative(a)                                                 |  |                                 | 1,488 |   |                                |   | 1,065 |      |  |   | 3,745  |   |  |   | 3,130  |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Total operating expenses                                                      |  |                                 | 3,505 |   |                                |   | 3,258 |      |  |   | 10,169 |   |  |   | 9,800  |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Operating loss                                                                |  |                                 | (281  | ) |                                |   | (71   | )    |  |   | (684   | ) |  |   | (850   | )
|Other income/(expense), net                                                   |  |                                 | 6     |   |                                |   | (128  | )    |  |   | 37     |   |  |   | (296   | )
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Loss before income taxes                                                      |  |                                 | (275  | ) |                                |   | (199  | )    |  |   | (647   | ) |  |   | (1,146 | )
|Provision for income taxes                                                    |  |                                 |      |   |                                |   | (163  | )    |  |   |       |   |  |   | (163   | )
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Net loss                                                                      |  | $                               | (275  | ) |                                | $ | (362  | )    |  | $ | (647   | ) |  | $ | (1,309 | )
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Net loss per share - basic and diluted                                        |  | $                               | (0.05 | ) |                                | $ | (0.08 | )    |  | $ | (0.12  | ) |  | $ | (0.27  | )
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Weighted shares used to calculate basic and diluted net loss per share        |  |                                 | 5,589 |   |                                |   | 4,784 |      |  |   | 5,377  |   |  |   | 4,779  |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|(a)SFAS No. 123(R) stock-based compensation expense was allocated as follows: |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|                                                                              |  |                                 |       |  
|Cost of Revenues                                                              |  | $                               | 8     |   |                                |   |       |      |  | $ | 30     |   |  |   |        |  
|Research and development                                                      |  |                                 | 31    |   |                                |   |       |      |  |   | 108    |   |  |   |        |  
|Sales and marketing                                                           |  |                                 | 20    |   |                                |   |       |      |  |   | 61     |   |  |   |        |  
|General and administrative                                                    |  |                                 | 84    |   |                                |   |       |      |  |   | 239    |   |  |   |        |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  
|Total stock compensation expense                                              |  | $                               | 143   |   |                                |   |       |      |  | $ | 438    |   |  |   |        |  
|                                                                              |  |                                 |       |   |                                |   |       |      |  |   |        |   |  |   |        |  

Cost of revenues and operating expense for the three months and nine months ended September 30, 2006 includes
share-based compensation expense in accordance with Statement of Financial Accounting Standards No. 123(R), which the Company adopted on January 1, 2006. See Note 5 to the financial statements for additional information.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



5



---

##### Table of Contents

APPLIED IMAGING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)



|                                                                                          |  |                                |        |   |      |   |        |  
|----------------------------------------------------------------------------------------- |  | ------------------------------ | ------ | - | ---- | - | ------ | -
|                                                                                          |  | Nine Months EndedSeptember 30, |       
|                                                                                          |  | 2006                           |        |   | 2005 |  
|CASH FLOWS FROM OPERATING ACTIVITIES:                                                     |  |                                |        |   |      |   |        |  
|Net loss                                                                                  |  | $                              | (647   | ) |      | $ | (1,309 | )
|Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |  |                                |        |   |      |   |        |  
|Depreciation and amortization                                                             |  |                                | 340    |   |      |   | 548    |  
|Stock-based compensation                                                                  |  |                                | 438    |   |      |   | 20     |  
|Changes in operating assets and liabilities:                                              |  |                                |        |   |      |   |        |  
|Trade accounts receivable, net                                                            |  |                                | 255    |   |      |   | (161   | )
|Inventories                                                                               |  |                                | 110    |   |      |   | 821    |  
|Prepaid expenses and other current assets                                                 |  |                                | 21     |   |      |   | 150    |  
|Other assets                                                                              |  |                                | 5      |   |      |   | (2     | )
|Accounts payable                                                                          |  |                                | 597    |   |      |   | (342   | )
|Accrued expenses                                                                          |  |                                | 293    |   |      |   | (343   | )
|Deferred revenue                                                                          |  |                                | (542   | ) |      |   | (243   | )
|Deferred rent                                                                             |  |                                | (70    | ) |      |   | (113   | )
|                                                                                          |  |                                |        |   |      |   |        |  
|Net cash provided by (used in) operating activities                                       |  |                                | 800    |   |      |   | (974   | )
|                                                                                          |  |                                |        |   |      |   |        |  
|CASH FLOWS FROM INVESTING ACTIVITIES:                                                     |  |                                |        |   |      |   |        |  
|Purchases of property and equipment                                                       |  |                                | (172   | ) |      |   | (220   | )
|                                                                                          |  |                                |        |   |      |   |        |  
|Net cash used in investing activities                                                     |  |                                | (172   | ) |      |   | (220   | )
|                                                                                          |  |                                |        |   |      |   |        |  
|CASH FLOWS FROM FINANCING ACTIVITIES:                                                     |  |                                |        |   |      |   |        |  
|Net proceeds from private placement                                                       |  |                                | 1,065  |   |      |   | (107   | )
|Bank and other loan proceeds                                                              |  |                                | 7,875  |   |      |   | 9,210  |  
|Bank and other loan payments                                                              |  |                                | (9,288 | ) |      |   | (8,762 | )
|Restricted cash                                                                           |  |                                | 4      |   |      |   | 17     |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Net cash provided by (used in) financing activities                                       |  |                                | (344   | ) |      |   | 358    |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Effect of exchange rate changes                                                           |  |                                | (65    | ) |      |   | 66     |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Net increase (decrease) in cash and cash equivalents                                      |  |                                | 219    |   |      |   | (770   | )
|                                                                                          |  |                               
|Cash and cash equivalents at beginning of year                                            |  |                                | 3,136  |   |      |   | 3,927  |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Cash and cash equivalents at end of quarter                                               |  | $                              | 3,355  |   |      | $ | 3,157  |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Supplemental disclosure of cash flow information:                                         |  |                                |        |   |      |   |        |  
|Cash paid for interest                                                                    |  | $                              | 42     |   |      | $ | 66     |  
|                                                                                          |  |                                |        |   |      |   |        |  
|Supplemental disclosure of non-cash investing and financing activities:                   |  |                                |        |   |      |   |        |  
|Inventory transfers to property and equipment                                             |  | $                              | 71     |   |      | $ | 149    |  
|                                                                                          |  |                                |        |   |      |   |        |  

The accompanying notes are an integral part of these unaudited condensed consolidated financial
statements.



6



---

##### Table of Contents

APPLIED IMAGING CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 Basis of Presentation

Description of Business and Recent Corporate Development

Applied Imaging Corp (the Company) was incorporated in California in July 1986 and subsequently reincorporated in Delaware in October 1996 and
develops, manufactures, and markets automated imaging and image analysis systems for use in cytogenetic laboratories for cancer testing, prenatal testing and other genetic testing applications and in pathology laboratories for cancer research and
diagnostics. The Company sells products to government and private clinical laboratories, research institutions, universities, and pharmaceutical companies located in North America, Europe and Asia. The Company also markets imaging systems designed
for use in plant and animal genetic research programs. The Company currently has under development a system for the detection, quantification and characterization of circulating tumor cells in the blood of cancer patients. This system, when
available, may allow physicians to better determine the initial staging of cancer cases, to detect disease recurrence earlier than is currently possible and to characterize cancer cells. The Company is headquartered in San Jose, California, and has
additional facilities in the United Kingdom. The Companys products are sold worldwide through a direct sales force, third-party distributors and independent sales representatives.

On August 31, 2006, the Company entered into an Agreement and Plan of Merger (or the Merger Agreement) with Genetix Group plc, or
Genetix, a corporation organized under the laws of the United Kingdom and Alpine Merger Corporation, a Delaware corporation and a wholly-owned subsidiary of Genetix. As originally contemplated by the Merger Agreement, each holder of the
Companys common stock would receive $3.06 per share in cash. Consummation of the merger is subject to customary conditions, including approval of the Merger Agreement by the stockholders of the Company. The Merger Agreement contained certain
termination rights for both Genetix and the Company, and further provided that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Genetix a termination fee of up to $550,000.

Subsequent to August 31, the Merger Agreement has been amended (See Note 10).

Basis of Presentation

The accompanying condensed consolidated financial statements include
the accounts of Applied Imaging Corp. and subsidiaries (the Company, we, us, our) for the three and nine months ended September 30, 2006 and 2005. These financial statements are unaudited and
reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Companys financial position, operating results and cash flows for those interim periods
presented.

Unless the context otherwise indicates, all share and per share common stock information in this Quarterly Report reflects a
1-for-4 reverse stock split of the common stock effective May 20, 2005.

The results of operations for the three and nine months ended
September 30, 2006 are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2006. These condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto, for the year ended December 31, 2005, contained in the Companys Form 10-K filed with the Securities and Exchange Commission on March 29, 2006.

Management Estimates.The preparation of the condensed consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of
revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Stock-based
Compensation

During the first quarter of fiscal 2006, the Company adopted the provisions of, and account for stock-based
compensation in accordance with, the Financial Accounting Standards Boards (FASB) Statement of Financial Accounting Standards No. 123revised 2004 (SFAS 123R), Share-Based Payment which replaced
Statement of Financial Accounting Standards No. 123 (SFAS 123), Accounting for Stock-Based Compensation and supersedes APB Opinion No. 25 (APB 25), Accounting for Stock Issued to Employees.
Under the fair value recognition provisions of this



7



---

##### Table of Contents

statement, stock-based compensation cost is measured at the grant date based on the fair value of the award and is
recognized as expense on a ratable basis over the requisite service period, which is the vesting period. The Company elected the modified-prospective method, under which prior periods are not revised for comparative purposes. The valuation
provisions of SFAS 123R apply to new grants and to grants that were outstanding as of the effective date and are subsequently modified. Estimated compensation for grants that were outstanding as of the effective date will be recognized over the
remaining service period using the compensation cost estimated in the prior SFAS 123 pro forma disclosures.

The adoption of SFAS 123R had
a material impact on the Companys consolidated financial position, results of operations and cash flows. See Note 5 for further information regarding the Companys stock-based compensation assumptions and expenses, including pro- forma
disclosures for prior periods as if the Company had recorded stock-based compensation expense during these periods.

NOTE 2  Inventories (in thousands)



|                    |  |                   |     |                  |   |    
|------------------- |  | ----------------- | --- | ---------------- | - | ---
|                    |  | September 30,2006 |     | December 31,2005
|Raw materials       |  | $                 | 229 |                  | $ | 350
|Work in progress    |  |                   | 12  |                  |   | 1  
|Finished goods      |  |                   | 19  |                  |   | 83 
|                    |  |                   |     |                  |   |    
|Total net inventory |  | $                 | 260 |                  | $ | 434
|                    |  |                   |     |                  |   |    

Inventories are stated at the lower of cost (determined on a first in, first out method) or
market. The Company records provisions to write down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of the inventory and its estimated market value based upon assumptions about future
market demand and market conditions. If future demand or market conditions are less favorable than currently expected, additional inventory provisions may be required.

NOTE 3  Commitments and Contingencies

In December 2006, the Companys Board of Directors approved equity and cash incentives to enhance benefits designed to retain employees of the Company as the Board considers strategic alternatives. The cash
component is payable upon the earlier of (i) January 1, 2007, (ii) six months after a change of control of the Company, or (iii) involuntary termination of the employee at any time after October 1, 2006 or the earlier entry
into a term sheet for a change of control. The Company presently anticipates this cash incentive to involve payment of $810,000. The Company has accrued an expense of $810,000 as of September 30, 2006.

Contractual Obligations. The following table presents certain payments due under contractual obligations with minimum firm commitments as of
September 30, 2006 (in thousands):



|                               |  |       |       |             |   |             |  |             |       |             |   |             |  |                           |     |  |   |   |  |   |  
|------------------------------ |  | ----- | ----- | ----------- | - | ----------- |  | ----------- | ----- | ----------- | - | ----------- |  | ------------------------- | --- |  | - | - |  | - | -
|                               |  | Total |       | Due in 2006 |   | Due in 2007 |  | Due in 2008 |       | Due in 2009 |   | Due in 2010 |  | Due in 2011and thereafter
|Bank loan(1)                   |  | $     | 641   |             | $ | 641         |  | $           |      |             | $ |            |  | $                         |    |  | $ |  |  | $ | 
|Operating lease commitments(2) |  |       | 1,708 |             |   | 203         |  |             | 755   |             |   | 561         |  |                           | 189 |  |   |  |  |   | 
|Vendor commitments(3)          |  |       | 480   |             |   | 480         |  |             |      |             |   |            |  |                           |    |  |   |  |  |   | 
|Retention incentives(4)        |  |       | 810   |             |   |            |  |             | 810   |             |   |            |  |                           |    |  |   |  |  |   | 
|                               |  |       |       |             |   |             |  |             |       |             |   |             |  |                           |     |  |   |   |  |   |  
|Total contractual obligations  |  | $     | 3,639 |             | $ | 1,324       |  | $           | 1,565 |             | $ | 561         |  | $                         | 189 |  | $ |  |  | $ | 
|                               |  |       |       |             |   |             |  |             |       |             |   |             |  |                           |     |  |   |   |  |   |  

---

|(1) | The Companys loan agreement with SVB terminates on March 29, 2007.
|--- | -------------------------------------------------------------------

|(2) | The Company has various non-cancelable operating leases for equipment, vehicles and facilities expiring through 2009. The facility leases generally contain renewal options for
periods ranging from two to five years and require the Company to pay all executory costs such as maintenance, property taxes, and insurance. The Companys primary lease
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



8



---

##### Table of Contents

| | commitment is for its facility in San Jose, California. The lease is for 24,095 square feet of office space. The lease on the San Jose facility is effective July 1, 2004
through September 30, 2009 with increasing annual rent commencing at $318,000, excluding operating expenses. However, rent expense is recognized on a straight-line basis. The 2005 rent expense was $325,000. Also, the Company leases a 4,422
square foot service office in League, Texas for $7,739 per month until the end of the lease in October 2006. In addition, the Company leases facilities in the United Kingdom, which aggregate approximately $302,445, excluding expenses per year
through 2008.
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | These commitments are generally for inventory, operating supplies/equipment, investor relations and for financing of D&O and employment practice insurance.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------

|(4) | The Board and Management have approved equity and cash incentives to enhance benefits designed to retain employees of the Company as the Board considers strategic alternatives.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NOTE 4  Net loss per share

Statement of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share, requires a dual presentation of basic and
diluted earnings per share (EPS). Basic EPS excludes dilution and is computed by dividing net income or loss by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential
dilution that would occur if outstanding securities to issue common stock were exercised or converted to common stock. Diluted net loss per share for the three and nine months ended September 30, 2006 and 2005 does not differ from basic net
loss per share since potential shares of common stock issuable upon exercise of stock options and warrants are anti-dilutive under the treasury stock method.

The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share amounts):



|                                          |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|----------------------------------------- |  | ------------------------------- | ----- | - | ------------------------------ | - | ----- | ---- |  | - | ----- | - |  | - | ------ | -
|                                          |  | Three Months EndedSeptember 30, |       |   | Nine Months EndedSeptember 30, |  
|                                          |  | 2006                            |       |   | 2005                           |   |       | 2006 |  |   | 2005  |  
|Numerator - Basic and Diluted             |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|Net loss                                  |  | $                               | (275  | ) |                                | $ | (362  | )    |  | $ | (647  | ) |  | $ | (1,309 | )
|                                          |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|Denominator - Basic and Diluted           |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|Weighted average shares outstanding basic |  |                                 | 5,589 |   |                                |   | 4,784 |      |  |   | 5,377 |   |  |   | 4,779  |  
|Dilutive shares - stock options           |  |                                 |      |   |                                |   |      |      |  |   |      |   |  |   |       |  
|Dilutive shares - warrants                |  |                                 |      |   |                                |   |      |      |  |   |      |   |  |   |       |  
|                                          |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|Weighted average shares outstanding basic |  |                                 | 5,589 |   |                                |   | 4,784 |      |  |   | 5,377 |   |  |   | 4,779  |  
|                                          |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  
|Basic and Diluted net loss per share      |  | $                               | (0.05 | ) |                                | $ | (0.08 | )    |  | $ | (0.12 | ) |  | $ | (0.27  | )
|                                          |  |                                 |       |   |                                |   |       |      |  |   |       |   |  |   |        |  

Securities excluded from the computation of EPS because their effect on EPS was antidilutive, but
could dilute basic EPS in future periods are as follows (in thousands):



|         |  |               |  |       
|-------- |  | ------------- |  | ------
|         |  | September 30,
|         |  | 2006          |  | 2005  
|         |  | Shares        |  | Shares
|Options  |  | 961           |  | 888   
|Warrants |  | 465           |  | 369   
|Total    |  | 1,426         |  | 1,257 

NOTE 5  Stock Based Compensation

Stock Compensation

Beginning with the Companys
first quarter of fiscal 2006, the Company adopted SFAS 123R. See Note 1 for a description of the Companys adoption of SFAS 123R. The Company uses the Black-Scholes option pricing model to



9



---

##### Table of Contents

determine the fair value of stock options. The determination of the fair value of stock-based payment awards on the date
of grant using an option-pricing model is affected by the Companys stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Companys expected stock price volatility over the
term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends.

Prior
to the adoption of SFAS 123R, the Company provided disclosures required under FAS No. 123 for stock-based compensation, amended by SFAS NO. 148, Accounting for Stock-Based Compensation Transition and Disclosures. The estimated
compensation cost is based on the fair value of the Companys common stock on the date of grant. The Company will continue to recognize the compensation cost, net of estimated forfeitures, over the vesting term.

Prior to the Adoption of SFAS No. 123(R)

The pro-forma information for the three months and nine months ended September 30, 2005 was as follows (in thousands, except per share data):



|                                                                             |  |                                      |       |   |                                     |   |        |  
|---------------------------------------------------------------------------- |  | ------------------------------------ | ----- | - | ----------------------------------- | - | ------ | -
|                                                                             |  | Three Months EndedSeptember 30, 2005 |       |   | Nine Months EndedSeptember 30, 2005 |  
|Net loss:                                                                    |  |                                      |       |   |                                     |   |        |  
|As reported                                                                  |  | $                                    | (362  | ) |                                     | $ | (1,309 | )
|Stock-based employee compensation expense determined under fair-value method |  |                                      | (85   | ) |                                     |   | (242   | )
|                                                                             |  |                                      |       |   |                                     |   |        |  
|Pro forma                                                                    |  | $                                    | (447  | ) |                                     | $ | (1,551 | )
|                                                                             |  |                                      |       |   |                                     |   |        |  
|Net loss per share:                                                          |  |                                      |       |   |                                     |   |        |  
|As reported:                                                                 |  |                                      |       |   |                                     |   |        |  
|Basic and diluted                                                            |  | $                                    | (0.08 | ) |                                     | $ | (0.27  | )
|                                                                             |  |                                      |       |   |                                     |   |        |  
|Pro forma                                                                    |  |                                      |       |   |                                     |   |        |  
|Basic and diluted                                                            |  | $                                    | (0.09 | ) |                                     | $ | (0.32  | )
|                                                                             |  |                                      |       |   |                                     |   |        |  

Impact of the Adoption of SFAS No. 123(R)

The Company elected to adopt the modified prospective application method as provided by SFA No. 123 (R). The effect of recording stock-based
compensation for the three months and nine months ended September 30, 2006 was as follows (in thousands, except per share data):



|                                                          |  |                                      |       |   |                                     |   |       |  
|--------------------------------------------------------- |  | ------------------------------------ | ----- | - | ----------------------------------- | - | ----- | -
|                                                          |  | Three Months EndedSeptember 30, 2006 |       |   | Nine Months EndedSeptember 30, 2006 |  
|Share-based compensation expense impact by type of award: |  |                                      |       |   |                                     |   |       |  
|                                                          |  |                                     
|As reported                                               |  | $                                    | (275  | ) |                                     | $ | (647  | )
|Stock plans                                               |  | $                                    | 133   |   |                                     | $ | 425   |  
|Employee stock purchase plan                              |  | $                                    | 10    |   |                                     | $ | 13    |  
|Effect on loss from continuing operations                 |  | $                                    | (143  | ) |                                     | $ | (438  | )
|Effect on loss before income taxes                        |  | $                                    | (143  | ) |                                     | $ | (438  | )
|Effect on Net loss                                        |  | $                                    | (143  | ) |                                     | $ | (438  | )
|Effect on cash flow from operations                       |  | $                                    |      |   |                                     | $ |      |  
|Effect on basic and diluted net loss per share            |  | $                                    | (0.03 | ) |                                     | $ | (0.08 | )

The total compensation cost related to nonvested awards not yet recognized as of
September 30, 2006 was approximately $732,000. The weighted-average period over which this compensation cost is expected to be recognized is 3.0 years.



10



---

##### Table of Contents

There were no stock option exercises for the three or nine month period ended September 30, 2006.
The Company did not receive any cash from option exercises nor pay any cash to settle stock options. In addition, the Company did not realize any tax benefit from stock option exercises for the three or nine months ended September 30, 2006.

Valuation Assumptions

The Company estimates the fair value of stock options using a Black-Scholes valuation model, consistent with the provisions of SFAS No. 123 (R), SEC SAB No. 107 and the Companys prior period pro forma disclosures of net
loss, including stock-based compensation (determined under a fair value method as prescribed by SFAS No. 123). The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model and the ratable
attribution approach with the following weighted-average assumptions:



|                         |  |              |   |  |             |   |  |                |   |  |                |  
|------------------------ |  | ------------ | - |  | ----------- | - |  | -------------- | - |  | -------------- | -
|                         |  | Three Months |   |  | Nine Months |  
|                         |  | 2006         |   |  | 2005        |   |  | 2006           |   |  | 2005           |  
|Expected life (in years) |  | 5            |   |  | 5           |   |  | 5              |   |  | 5              |  
|Volatility               |  | 82.15        | % |  | 84.00       | % |  | 82.15% - 82.50 | % |  | 84.00% - 92.00 | %
|Risk free interest rate  |  | 4.76         | % |  | 3.40        | % |  | 4.68% - 5.02   | % |  | 3.40% - 3.66   | %
|Dividend yield           |  |             | % |  |            | % |  |   % -        | % |  |   % -        | %

The dividend yield is based on the fact that the Company has never paid cash dividends and has no
present intention to pay cash dividends. Expected volatility is based on the combination of historical volatility of the Companys common stock, the expected moderation in future volatility over the period commensurate with the expected life of
options and other factors. The risk free interest rates are taken from the Daily Federal Yield Curve Rates as of the grant dates as published by the Federal Reserve and represents the yield on actively traded treasury securities for terms equal to
the expected term of the options. The expected term calculation is based on observed historical option exercise behavior, post-vesting employment termination behavior of the Companys employees and the options contractual term.

Equity Incentive Program

As of September 30, 2006, the Company had the following stock plans:



|                                  |  |                       |  |                            |  |                    
|--------------------------------- |  | --------------------- |  | -------------------------- |  | -------------------
|                                  |  | Reserved for Issuance |  | Shares Available for Grant |  | Options Outstanding
|1998 Incentive Stock Option Plan  |  | 1,186,959             |  | 331,037                    |  | 855,922            
|1988 Incentive Stock Option Plan  |  | 27,608                |  |                           |  | 27,608             
|1994 Directors Stock Option Plan |  | 27,500                |  |                           |  | 27,500             
|2003 Stand-Alone Option Plan      |  | 50,000                |  |                           |  | 50,000             
|                                  |  |                       |  |                            |  |                    
|Totals                            |  | 1,292,067             |  | 331,037                    |  | 961,030            
|                                  |  |                       |  |                            |  |                    

Under the 1998 Stock Plan, stock options may be granted to Board members, officers, key employees,
and consultants at the fair market value of the common stock at the date of the grant, as determined by the Board of Directors, typically the closing share price on the day of grant. Options are exercisable over 10 years from the date of grant, and
typically vest ratably over 4 years.

The Companys 1988 Stock Plan expired in October 1998. No options were granted in this Plan
after October 1998.

The Companys 1994 Directors Option Plan was enacted and designed to encourage participation on the
Companys Board of Directors. The terms of the plan allow the granting of stock options upon initial election to the Board of Directors and for subsequent grants.

The Companys 2003 Stand-Alone Plan was established in November 2003 designed to offer incentive options to a key new employee.



11



---

##### Table of Contents

The following table sets forth the summary of option activity under the Companys stock option
program for the nine months ended September 30, 2006:



|                                                     |  |                           |   |  |                               |      |                                |      |                          |   |        
|---------------------------------------------------- |  | ------------------------- | - |  | ----------------------------- | ---- | ------------------------------ | ---- | ------------------------ | - | -------
|                                                     |  | OptionsAvailable forGrant |   |  | WeightedAverage ExercisePrice |      | WeightedAverageContractualLife |      | Aggregate IntrinsicValue
|Beginning at December 31, 2005                       |  | 1,076,903                 |   |  | $                             | 4.45 |                                |      |                          |   |        
|                                                     |  |                           |   | 
|Options granted                                      |  | 41,750                    |   |  | $                             | 1.91 |                                |      |                          |   |        
|Options exercised                                    |  |                          |   |  | $                             |     |                                |      |                          |   |        
|Options forfeited                                    |  | (16,184                   | ) |  | $                             | 2.89 |                                |      |                          |   |        
|Options expired                                      |  | (141,439                  | ) |  | $                             | 8.65 |                                |      |                          |   |        
|                                                     |  |                           |   |  |                               |      |                                |      |                          |   |        
|Outstanding at September 30, 2006                    |  | 961,030                   |   |  | $                             | 3.75 |                                | 7.54 |                          | $ | 949,973
|                                                     |  |                           |   |  |                               |      |                                |      |                          |   |        
|Vested and expected to vest at September 30, 2006(1) |  | 876,389                   |   |  | $                             | 3.97 |                                | 0.71 |                          | $ | 817,779
|                                                     |  |                           |   |  |                               |      |                                |      |                          |   |        
|Exercisable at September 30, 2006                    |  | 369,544                   |   |  | $                             | 7.15 |                                | 5.21 |                          | $ | 51,805 
|                                                     |  |                           |   |  |                               |      |                                |      |                          |   |        

---

|(1) | The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total outstanding options.
|--- | ---------------------------------------------------------------------------------------------------------------------------------



|                           |  |                   |  |                                     |  |                               |       |                   |         |                               |   |      
|-------------------------- |  | ----------------- |  | ----------------------------------- |  | ----------------------------- | ----- | ----------------- | ------- | ----------------------------- | - | -----
|Range of Exercise Prices   |  | NumberOutstanding |  | WeightedAverageRemainingContractual |  | WeightedAverageExercise Price |       | NumberExercisable |         | WeightedAverageExercise Price
|$1.21                $1.21 |  | 419,000           |  | 9.22                                |  | $                             | 1.21  |                   |        |                               |   |     
|$1.65                $2.24 |  | 107,593           |  | 8.79                                |  | $                             | 2.06  |                   | 27,116  |                               | $ | 2.14 
|$2.28                $3.04 |  | 106,875           |  | 8.42                                |  | $                             | 2.37  |                   | 41,732  |                               | $ | 2.40 
|$3.48                $4.88 |  | 97,487            |  | 5.24                                |  | $                             | 3.99  |                   | 86,881  |                               | $ | 3.96 
|$5.44                $9.60 |  | 129,726           |  | 5.57                                |  | $                             | 7.19  |                   | 113,466 |                               | $ | 7.40 
|$9.75              $12.00  |  | 52,599            |  | 2.38                                |  | $                             | 10.76 |                   | 52,599  |                               | $ | 10.76
|$13.75            $13.75   |  | 6,500             |  | 3.84                                |  | $                             | 13.75 |                   | 6,500   |                               | $ | 13.75
|$14.50            $14.50   |  | 9,750             |  | 3.90                                |  | $                             | 14.50 |                   | 9,750   |                               | $ | 14.50
|$16.00            $16.00   |  | 24,125            |  | 3.61                                |  | $                             | 16.00 |                   | 24,125  |                               | $ | 16.00
|$16.12            $16.12   |  | 7,375             |  | 4.11                                |  | $                             | 16.12 |                   | 7,375   |                               | $ | 16.12
|                           |  |                   |  |                                     |  |                               |       |                   |         |                               |   |      
|$1.21              $16.12  |  | 961,030           |  | 7.54                                |  | $                             | 3.75  |                   | 369,544 |                               | $ | 7.15 
|                           |  |                   |  |                                     |  |                               |       |                   |         |                               |   |      

The aggregate intrinsic value in the table above represents the total intrinsic value (the
aggregate difference between the closing stock price of the Companys common stock on September 30, 2006 and the exercise price of in-the-money options) that would have been received by the option holders if all option had been exercised
on September 30, 2006.

The weighted average grant date fair value of options granted during the quarter ended September 30, 2006
was $1.65.

Information regarding the stock options outstanding and exercisable at September 30, 2006 is summarized below:

Employee Stock Purchase Plan

In 2005, the
Companys prior Employee Stock Purchase Plan (ESPP) was discontinued. At the Companys 2006 meeting of stockholders, the stockholders approved, among other things, the adoption of the Companys 2006 Employee Stock Purchase
Plan and a reservation of a total of 175,000 shares of common stock for purchase under the 2006 Purchase Plan.

The 2006 Employee Stock
Purchase Plan allowed eligible employees of Applied Imaging to purchase shares of its common stock through a payroll-deduction based employee stock purchase plan designed to qualify under Section 423 of the Internal Revenue Code. The 2006
Employee Stock Purchase Plan consists of two six month offering periods. Employees purchase shares in each purchase period at 85% of the market value of the Companys common stock at either the beginning of the offering period or the end of the
purchase period, whichever price is lower.



12



---

##### Table of Contents

The estimated fair value of purchase rights under the Companys Purchase Plan was determined using
the Black-Scholes pricing model with the following assumptions for the period ending September 30, 2006:



|                         |  |                          |  
|------------------------ |  | ------------------------ | -
|                         |  | Three and Six Months2006 |  
|Expected life (in years) |  | 6 months                 |  
|Volatility               |  | 53.88                    | %
|Risk free interest rate  |  | 5.06                     | %
|Dividend yield           |  |                         | %

NOTE 6  Product Warranty

The Company generally warrants its products against defects for a period of one year and records a liability for such product warranty obligations at the
time of sale based upon historical experience. The Company sells separately priced service contracts to provide additional service coverage on its systems when the warranty period expires. The related revenue on the service contracts is recognized
on a straight-line basis over the life of the service contract, which is generally one year. Costs associated with services performed under the service contract obligation are expensed as incurred.

Changes in product warranty obligations are as follows (in thousands):



|                                            |  |                   |      |   |                   |   |      |  
|------------------------------------------- |  | ----------------- | ---- | - | ----------------- | - | ---- | -
|                                            |  | September 30,2006 |      |   | September 30,2005 |  
|Balances at Beginning of Year               |  | $                 | 183  |   |                   | $ | 101  |  
|Add: accruals for warranties issued         |  |                   | 102  |   |                   |   | 171  |  
|Less: cost incurred under warranties issued |  |                   | (124 | ) |                   |   | (114 | )
|                                            |  |                   |      |   |                   |   |      |  
|Balance end of quarter                      |  | $                 | 161  |   |                   | $ | 158  |  
|                                            |  |                   |      |   |                   |   |      |  

NOTE 7  Segment and Geographic

The Company has historically reported as one segment, namely, the imaging business. In late 2004, the Company formed a subsidiary CTC with the
intent to develop a commercial system for the detection, quantification and analysis of circulating tumor cells in blood. The Company began very early stage research and development activities on CTC in 2005 and the program was managed as a research
and development project within existing management and financial reporting structures.

In Q1 2006, as part of the 2006 planning effort,
the Company organized itself in a way to give focus to its CTC effort. The Chief Operating Decision Maker now reviews financial results by two segments, namely, the imaging business and CTC. Managements determination is that CTC moved from a
project to a fully functional research and development program with management, initial funding, management focus, internal financial reporting segmentation and formal resource allocation segmentation during Q1 2006.



13



---

##### Table of Contents

A reconciliation of the totals reported for the operating segments to the applicable line items in the
condensed consolidated financial statements for the nine months periods ended September 30, 2006 and September 30, 2005 follows:



|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|------------------------------------------ |  | --------------- | ------ | - | --- | - | ------ | ------------------ |  | - | ------ | -
|                                           |  | ImagingBusiness |        |   | CTC |   |        | Total Consolidated | 
|Nine Month Period ended September 30, 2006 |  |                 |        |   |     |   |        |                    |  |   |        |  
|Revenue                                    |  | $               | 14,989 |   |     | $ |       |                    |  | $ | 14,989 |  
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|Operating Expenses                         |  |                 | 9,032  |   |     |   | 1,137  |                    |  |   | 10,169 |  
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|Net Income (Loss)                          |  | $               | 490    |   |     | $ | (1,137 | )                  |  | $ | (647   | )
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|Nine Month Period ended September 30, 2006 |  |                 |        |   |     |   |        |                    |  |   |        |  
|Revenue                                    |  | $               | 14,735 |   |     | $ |       |                    |  | $ | 14,735 |  
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|Operating Expenses                         |  |                 | 8,712  |   |     |   | 1,088  |                    |  |   | 9,800  |  
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  
|Net Loss                                   |  | $               | (221   | ) |     | $ | (1,088 | )                  |  | $ | (1,309 | )
|                                           |  |                 |        |   |     |   |        |                    |  |   |        |  

Total operating expenses comprise research and development, sales and marketing and general and
administrative except for CTC which does not have general and administrative expenses. For fiscal 2006, operating expense also included stock-based compensation.

A reconciliation of the totals reported for the operating segments to the applicable line items in the condensed consolidated financial statements for the quarters ended September 30, 2006 and December 31,
2005 is as follows in thousands:

The following table presents net revenues by geographic region in thousands:



|                                 |  |              |       |                |   |       |             |    |                |  |   |        |  |   |        |  |    |  
|-------------------------------- |  | ------------ | ----- | -------------- | - | ----- | ----------- | -- | -------------- |  | - | ------ |  | - | ------ |  | -- | -
|                                 |  | Three Months |       | Percent Change |   |       | Nine Months |    | Percent Change | 
|                                 |  | 2006         |       | 2005           |   |       | 2006        |    | 2005           | 
|North America                    |  |              | 3,565 |                |   | 3,373 |             | 6  | %              |  |   | 9,989  |  |   | 9,676  |  | 3  | %
|International-Principally Europe |  |              | 1,526 |                |   | 1,560 |             | -2 | %              |  |   | 5,000  |  |   | 5,059  |  | -1 | %
|                                 |  |              |       |                |   |       |             |    |                |  |   |        |  |   |        |  |    |  
|Total revenues                   |  | $            | 5,091 |                | $ | 4,933 |             | 3  | %              |  | $ | 14,989 |  | $ | 14,735 |  | 2  | %
|                                 |  |              |       |                |   |       |             |    |                |  |   |        |  |   |        |  |    |  

NOTE 8  Goodwill

The carrying value of goodwill was $2.4 million as of September 30, 2006 and December 31, 2005, respectively, and was allocated to Applied Imagings imaging business reporting segment pursuant to SFAS
No. 142. In accordance with SFAS No. 142, Applied Imaging completed its annual evaluation of the goodwill by reporting unit during the quarter ended March 31, 2006, and concluded that there was no impairment.

Reclassifications

Certain
reclassifications related to patent expenses have been made from R&D to G&A to be consistent with prior year presentation.

NOTE 9 
Income Taxes

As of August 31, 2006, the Companys federal and state net operating loss (NOL) carry forwards
were $46.8 million and $7.3 million, respectively. The Companys federal and state tax credits are $723,000 and $617,000 respectively. As a result of cumulative stock ownership changes in April 1993, June 1998 and August 2006, the
Companys net operating losses and tax credits carry forwards are limited in use to approximately $1.6 million per year through fiscal year end 2011 and $924,000 per year through fiscal year end 2026. Approximately, $24.3 million of the
Companys federal NOL and $723,000 of the Companys federal research and development credits will expire before utilization.



14



---

##### Table of Contents

NOTE 10  Subsequent Events

On October 20, 2006, the Company entered into Amendment No. 1 to the Merger Agreement. The amendment increased the cash consideration payable to
our stockholders in the proposed merger transaction with Genetix from $3.06 per share to $3.50 per share. The amendment also increased the maximum amount payable to Genetix upon the termination of the proposed merger transaction due to certain
circumstances from $550,000 to $950,000.

On October 27, 2006, the Company entered into Amendment No. 2 to the Merger Agreement.
The amendment increased the cash consideration payable to the Companys stockholders in the proposed merger transaction with Genetix from $3.50 per share to $3.70 per share. The amendment to the Merger Agreement also increased the maximum
amount payable to Genetix upon the termination of the proposed merger transaction due to certain circumstances from $950,000 to $1,010,000.

On October 30, 2006, the Board of Directors of the Company authorized the termination of Applied Imaging Corp.s 2006 Employee Stock Purchase Plan, or ESPP, effective as of November 1, 2006. The ESPP allowed eligible employees of
Applied Imaging to purchase shares of its common stock through a payroll-deduction based employee stock purchase plan designed to qualify under Section 423 of the Internal Revenue Code. The Board of Directors terminated the ESPP as required by the
Agreement and Plan of Merger by and among Genetix Group plc, Alpine Merger Corporation, and Applied Imaging dated August 31, 2006, as amended to date.

On November 2, 2006, the Company entered into Amendment No. 3 to the Merger Agreement. The amendment increased the cash consideration payable to the Companys stockholders in the Companys proposed
merger transaction with Genetix from $3.70 per share to $3.80 per share. The amendment also increased the maximum amount payable to Genetix upon the termination of the proposed merger transaction due to certain circumstances from $1,010,000 to
$1,040,000.

On November 9, 2006, the Company entered into Amendment No. 4 to the Merger Agreement. The amendment increased the
cash consideration payable to the Companys stockholders in the Companys proposed merger transaction with Genetix from $3.70 per share to $4.20 per share. The amendment also increased the maximum amount payable to Genetix upon the
termination of the proposed merger transaction due to certain circumstances from $1,040,000 to $1,161,000.

A special meeting of the
Companys stockholders will be held on Tuesday, November 21, 2006 at the Companys principal offices in San Jose, California for the primary purpose to consider and vote upon a proposal to adopt the Agreement and Plan of Merger, dated
as of August 31, 2006, as amended on October 20, 2006, October 27, 2006 and November 2, 2006. If the Merger Agreement is adopted by the Companys stockholders, then upon the terms and subject to the conditions set forth
in the Merger Agreement, The Company will become a wholly-owned subsidiary of Genetix.

NOTE 11  Recently Issued Accounting Prouncements

In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB
Statement No. 109 (FIN 48), which prescribes accounting for and disclosure of uncertainty in tax positions. This interpretation defines the criteria that must be met for the benefits of a tax position to be recognized. The provisions of FIN 48
are effective as of the beginning of the Companys 2007 fiscal year, with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. The Company is currently evaluating the impact of
adopting FIN 48 on its financial statements.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108 (SAB
108), Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. SAB 108 is effective for fiscal years ending on or after November 15, 2006 and addresses how
financial statement errors should be considered from a materiality perspective and corrected. The literature provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in
quantifying a current year misstatement. Historically there have been two common approaches used to quantify such errors: (i) the rollover approach, which quantifies the error as the amount by which the current year income statement
is misstated, and (ii) the iron curtain approach, which quantifies the error as the cumulative amount by which the current year balance sheet is misstated. The SEC Staff believes that companies should quantify errors using both
approaches and evaluate whether either of these approaches results in quantifying a misstatement that, when all relevant quantitative and qualitative factors are considered, is material. The Company is currently evaluating the impact, if any, of
adopting the provisions of SAB 108 on our financial position, results of operations and liquidity.



15



---

##### Table of Contents

In September 2006, the FASB issued SFAS No. 157 Fair Value Measurements (SFAS
157), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 is effective in fiscal years beginning after
November 15, 2007. The Company is currently assessing the impact of adopting SFAS 157 on the consolidated financial condition, results of operations, and cash flows of the Company.

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

The
following discussion should be read in conjunction with the attached unaudited condensed consolidated financial statements and notes, and with our audited financial statements and notes for the fiscal year ended December 31, 2005.

This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual
results could differ materially from those predicted in the forward-looking statements as a result of risks and uncertainties including, but not limited to, those discussed in this quarterly report and those discussed under Item 1 
Business, Additional Factors That Might Affect Future Results, and under Item 7  Managements Discussion And Analysis of Financial Condition And Results of Operations commencing on pages 11 and 22 in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2005. You should not rely on these forward-looking statements, which reflect our position as of the date of this report. We are under no obligation to revise or update any forward-looking
statements.

Pending Merger

On August 31, 2006, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Genetix Group plc, or Genetix, a corporation organized under the laws of the United Kingdom and Alpine Merger
Corporation, a Delaware corporation and a wholly-owned subsidiary of Genetix. As originally contemplated by the Merger Agreement, each holder of our common stock would receive $3.06 per share in cash. Consummation of the merger is subject to
customary conditions, including approval of the Merger Agreement by our stockholders. The Merger Agreement contained certain termination rights for both Genetix and us, and further provided that, upon termination of the Merger Agreement under
specified circumstances, we may be required to pay Genetix a termination fee of up to $550,000.

On October 20, 2006, the Company
entered into Amendment No. 1 to the Merger Agreement. The amendment increased the cash consideration payable to our stockholders in the proposed merger transaction with Genetix from $3.06 per share to $3.50 per share. The amendment also
increased the maximum amount payable to Genetix upon the termination of the proposed merger transaction due to certain circumstances from $550,000 to $950,000.

On October 27, 2006, the Company entered into Amendment No. 2 to the Merger Agreement. The amendment increased the cash consideration payable to the Companys stockholders in the proposed merger
transaction with Genetix from $3.50 per share to $3.70 per share. The amendment to the Merger Agreement also increased the maximum amount payable to Genetix upon the termination of the proposed merger transaction due to certain circumstances from
$950,000 to $1,010,000.

On October 30, 2006, the Board of Directors of the Company authorized the termination of Applied Imaging
Corp.s 2006 Employee Stock Purchase Plan, or ESPP, effective as of November 1, 2006. The ESPP allowed eligible employees of Applied Imaging to purchase shares of its common stock through a payroll-deduction based employee stock purchase plan
designed to qualify under Section 423 of the Internal Revenue Code. The Board of Directors terminated the ESPP as required by the Agreement and Plan of Merger by and among Genetix Group plc, Alpine Merger Corporation, and Applied Imaging dated
August 31, 2006, as amended to date.

On November 2, 2006, the Company entered into Amendment No. 3 to the Merger Agreement. The
amendment increased the cash consideration payable to the Companys stockholders in the Companys proposed merger transaction with Genetix from $3.70 per share to $3.80 per share. The amendment also increased the maximum amount payable to
Genetix upon the termination of the proposed merger transaction due to certain circumstances from $1,010,000 to $1,040,000.

On
November 9, 2006, the Company entered into Amendment No. 4 to the Merger Agreement. The amendment increased the cash consideration payable to the Companys stockholders in the Companys proposed merger transaction with Genetix
from $3.70 per share to $4.20 per share. The amendment also increased the maximum amount payable to Genetix upon the termination of the proposed merger transaction due to certain circumstances from $1,040,000 to $1,161,000.

A special meeting of the Companys stockholders will be held on Tuesday, November 21, 2006 at the Companys principal offices in San Jose,
California for the primary purpose to consider and vote upon a proposal to adopt the Agreement and Plan of Merger, dated as of August 31, 2006, as amended on October 20, 2006, October 27, 2006 and November 2, 2006. If the
Merger Agreement is adopted by the Companys stockholders, then upon the terms and subject to the conditions set forth in the Merger Agreement, The Company will become a wholly-owned subsidiary of Genetix.



16



---

##### Table of Contents

Results of Operations

Revenues



|                             |  |              |       |   |                |   |       |             |      |    |                |      |   |        |   |  |   |        |   |  |    |  
|---------------------------- |  | ------------ | ----- | - | -------------- | - | ----- | ----------- | ---- | -- | -------------- | ---- | - | ------ | - |  | - | ------ | - |  | -- | -
|                             |  | Three Months |       |   | Percent Change |   |       | Nine Months |      |    | Percent Change |     
|                             |  | 2006         |       |   | 2005           |   |       |             | 2006 |    |                | 2005 |   |       
|Product                      |  | $            | 3,426 |   |                | $ | 3,493 |             |      | -2 | %              |      | $ | 10,294 |   |  | $ | 10,446 |   |  | -1 | %
|Percentage of total revenues |  |              | 67    | % |                |   | 71    | %           |      |    |                |      |   | 69     | % |  |   | 71     | % |  |    |  
|Service and support          |  |              | 1,665 |   |                |   | 1,440 |             |      | 16 | %              |      |   | 4,695  |   |  |   | 4,289  |   |  | 9  | %
|Percentage of total revenues |  |              | 33    | % |                |   | 29    | %           |      |    |                |      |   | 31     | % |  |   | 29     | % |  |    |  
|                             |  |              |       |   |                |   |       |             |      |    |                |      |   |        |   |  |   |        |   |  |    |  
|Total revenues               |  | $            | 5,091 |   |                | $ | 4,933 |             |      | 3  | %              |      | $ | 14,989 |   |  | $ | 14,735 |   |  | 2  | %
|                             |  |              |       |   |                |   |       |             |      |    |                |      |   |        |   |  |   |        |   |  |    |  

Our revenues are derived primarily from the sale of systems, service contracts, software
maintenance and grant revenues.

Overall revenue for the three and nine month periods ending September 30, 2006 were relatively flat
as compared to the same period in 2005.

System sales were flat in the three and nine month periods ending September 30, 2006 compared
to the same period in 2005.

Service contract and software maintenance revenues increased during the three and nine month periods ending
2006 compared to the same periods in 2005 primarily due to increased consulting revenues.

Cost of revenue



|                             |  |              |       |   |                |   |       |             |      |   |                |      |   |       |   |  |   |       |   |  |    |  
|---------------------------- |  | ------------ | ----- | - | -------------- | - | ----- | ----------- | ---- | - | -------------- | ---- | - | ----- | - |  | - | ----- | - |  | -- | -
|                             |  | Three Months |       |   | Percent Change |   |       | Nine Months |      |   | Percent Change |     
|                             |  | 2006         |       |   | 2005           |   |       |             | 2006 |   |                | 2005 |   |      
|Product                      |  | $            | 1,422 |   |                | $ | 1,309 |             |      | 9 | %              |      | $ | 4,138 |   |  | $ | 4,352 |   |  | -5 | %
|Percentage of total revenues |  |              | 76    | % |                |   | 75    | %           |      |   |                |      |   | 75    | % |  |   | 75    | % |  |    |  
|Service and support          |  |              | 445   |   |                |   | 437   |             |      | 2 | %              |      |   | 1,366 |   |  |   | 1,433 |   |  | -5 | %
|Percentage of total revenues |  |              | 24    | % |                |   | 25    | %           |      |   |                |      |   | 25    | % |  |   | 25    | % |  |    |  
|                             |  |              |       |   |                |   |       |             |      |   |                |      |   |       |   |  |   |       |   |  |    |  
|Total cost of revenues       |  | $            | 1,867 |   |                | $ | 1,746 |             |      | 7 | %              |      | $ | 5,504 |   |  | $ | 5,785 |   |  | -5 | %
|                             |  |              |       |   |                |   |       |             |      |   |                |      |   |       |   |  |   |       |   |  |    |  

Cost of revenues includes direct material and labor costs, manufacturing overhead, installation
costs, warranty-related expenses and service and application support expenses.

Cost of revenues, as a percentage of total revenues, for
the three months ended September 30, 2006 compared to the same period in 2005 increased due to product mix. Cost of revenues for the nine month period ending September 30, 2006 compared to the same period in 2005 was lower primarily due to
managements focus on reducing the material costs of systems. Also, high margin consulting revenues were achieved in the nine months ending September 30, 2006.

Research and development expenses



|                             |  |              |     |   |                |   |     |             |      |     |                |      |   |       |   |  |   |       |   |  |     |  
|---------------------------- |  | ------------ | --- | - | -------------- | - | --- | ----------- | ---- | --- | -------------- | ---- | - | ----- | - |  | - | ----- | - |  | --- | -
|                             |  | Three Months |     |   | Percent Change |   |     | Nine Months |      |     | Percent Change |     
|                             |  | 2006         |     |   | 2005           |   |     |             | 2006 |     |                | 2005 |   |      
|Research and development     |  | $            | 641 |   |                | $ | 800 |             |      | -20 | %              |      | $ | 2,142 |   |  | $ | 2,555 |   |  | -16 | %
|Percentage of total revenues |  |              | 13  | % |                |   | 16  | %           |      |     |                |      |   | 14    | % |  |   | 17    | % |  |     |  

Research and development (R&D) expenses consist primarily of salary and benefit
expenses for software developers, contracted development efforts, related facilities costs and expenses associated with computer equipment used in software development.

Research and development expenses decreased for the period ending September 30, 2006 compared to the same period of 2005 primarily due to $133,000 in patent expenses recorded in research and development expense
in the first and second quarters of 2006 which was reclassified to general and administrative expenses in the third quarter of 2006.

The
decrease in expenses for the nine months ending September 30, 2006 as compared to the same period in 2005 was primarily due to reduced consulting expense of $189,000, reclassification of $133,000 in patent expenses to general and
administrative, reduced supplies expenses of $108,000 and, lower personnel expenses of $143,000. These lower expenses were partially off-set by stock-based compensation of $108,000 and retention expenses of $40,000.



17



---

##### Table of Contents

Sales and marketing expenses



|                             |  |              |       |   |                |   |       |             |      |    |                |      |   |       |   |  |   |       |   |  |   |  
|---------------------------- |  | ------------ | ----- | - | -------------- | - | ----- | ----------- | ---- | -- | -------------- | ---- | - | ----- | - |  | - | ----- | - |  | - | -
|                             |  | Three Months |       |   | Percent Change |   |       | Nine Months |      |    | Percent Change |     
|                             |  | 2006         |       |   | 2005           |   |       |             | 2006 |    |                | 2005 |   |      
|Sales and marketing          |  | $            | 1,376 |   |                | $ | 1,393 |             |      | -1 | %              |      | $ | 4,282 |   |  | $ | 4,115 |   |  | 4 | %
|Percentage of total revenues |  |              | 27    | % |                |   | 28    | %           |      |    |                |      |   | 29    | % |  |   | 28    | % |  |   |  

Sales and marketing expenses include salary and benefit expenses, sales commissions, travel
expenses and related facilities costs for our sales, marketing, and order management personnel. Sales and marketing expenses also include the costs of programs aimed at increasing revenue, such as, trade shows, public relations and other market
development programs.

Sales and marketing expenses were relatively flat in the third quarter of 2006 compared to the same period in 2005.
Stock-based compensation expense was $20,000 in the quarter ending September 30, 2006.

Expenses for the first nine months ending
September 30, 2006 as compared to the same period in 2005 were higher primarily due to stock-based compensation of $61,000 and retention bonus of $193,000.

General and administrative expenses



|                             |  |              |       |   |               |   |       |             |      |    |               |      |   |       |   |  |   |       |   |  |    |  
|---------------------------- |  | ------------ | ----- | - | ------------- | - | ----- | ----------- | ---- | -- | ------------- | ---- | - | ----- | - |  | - | ----- | - |  | -- | -
|                             |  | Three Months |       |   | PercentChange |   |       | Nine Months |      |    | PercentChange |     
|                             |  | 2006         |       |   | 2005          |   |       |             | 2006 |    |               | 2005 |   |      
|General and administrative   |  | $            | 1,488 |   |               | $ | 1,065 |             |      | 40 | %             |      | $ | 3,745 |   |  | $ | 3,130 |   |  | 20 | %
|Percentage of total revenues |  |              | 29    | % |               |   | 22    | %           |      |    |               |      |   | 25    | % |  |   | 21    | % |  |    |  

General and administrative (G&A) expenses consist primarily of compensation and
benefit expenses, travel expenses, and related facilities costs for our finance, facilities, human resources, information services and executive personnel. General and administrative expenses also include outside legal and accounting fees, provision
for bad debts, expenses associated with computer equipment and software used in the administration of the business, and various forms of insurance.

G&A expenses increased in the third quarter of 2006 compared the same quarter in 2005 primarily due approximately $507,000 in expenses related to the Merger Agreement, Stock-based compensation of $84,000 which pertains to the
September 30, 2006 quarter was partially offset by an $88,000 net change in patent expenses previously recorded as R&D and $79,000 in lower consulting expenses.

G&A Expenses for the nine months ended September 30, 2006 were higher as compared to the same period in 2005 due to approximately $557,000 of costs related to the Merger Agreement, stock-based compensation of
$239,000 and retention bonus expense of $502,000. These expenses were offset by lower audit expenses of $223,000, lower consulting expenses of $205,000 and reduced patent expenses of $93,000 and lower non-merger and acquisition legal fees of
$64,000.

Other income (expense), net



|                                   |  |              |   |   |                |   |      |             |      |      |                |      |   |    |   |  |   |      |   |  |      |  
|---------------------------------- |  | ------------ | - | - | -------------- | - | ---- | ----------- | ---- | ---- | -------------- | ---- | - | -- | - |  | - | ---- | - |  | ---- | -
|                                   |  | Three Months |   |   | Percent Change |   |      | Nine Months |      |      | Percent Change |     
|                                   |  | 2006         |   |   | 2005           |   |      |             | 2006 |      |                | 2005 |   |   
|Non-Operating income(expense), Net |  | $            | 6 |   |                | $ | (128 | )           |      | -105 | %              |      | $ | 37 |   |  | $ | (296 | ) |  | -113 | %
|Percentage of total revenues       |  |              | 0 | % |                |   | -3   | %           |      |      |                |      |   | 0  | % |  |   | -2   | % |  |      |  

Non-operating income (expense) consists primarily of interest income, interest expense, foreign
remeasurement and transaction expense.

Non-operating income was higher in the three months and nine months ending September 30, 2006
as compared to the same periods in 2005 primarily due to the translation and transaction gains associated with our UK operations partially offset by $163,000 income tax expense related to a tax dispute in our UK operations that was settled in the
quarter ending September 30, 2005.



18



---

##### Table of Contents

Liquidity and Capital Resources



|                          |  |                   |       |                  |   |       |               |  |      |  
|------------------------- |  | ----------------- | ----- | ---------------- | - | ----- | ------------- |  | ---- | -
|                          |  | September 30,2006 |       | December 31,2005 |   |       | PercentChange | 
|Cash and cash equivalents |  | $                 | 3,355 |                  | $ | 3,136 |               |  | 7    | %
|Working capital           |  | $                 | 443   |                  | $ | (494  | )             |  | -190 | %
|Stockholders equity      |  | $                 | 3,211 |                  | $ | 2,353 |               |  | 36   | %



|                                                    |  |                   |      |   |                   |   |      |  
|--------------------------------------------------- |  | ----------------- | ---- | - | ----------------- | - | ---- | -
|                                                    |  | Nine Months Ended |     
|                                                    |  | September 30,2006 |      |   | September 30,2005 |  
|Net cash provided (used in) by operating activities |  | $                 | 800  |   |                   | $ | (974 | )
|Net cash used in investing activities               |  | $                 | (172 | ) |                   | $ | (220 | )
|Net cash provided by (used in) financing activities |  | $                 | (344 | ) |                   | $ | 358  |  

Our primary source of cash is receipts from revenue. The primary uses of cash are payroll
(salaries, bonuses, and benefits), general operating expenses (marketing, travel, office rent) and cost of product revenue. Another source of cash is proceeds from private equity financing such as the one which occurred in March 2006.

Working capital

The increase in
working capital from December 2005 to September 2006 resulted primarily from the net proceeds of $1.1 million from a March 2006 private placement.

Stockholders equity

The increase in stockholders equity from December 2005 to September 2006 resulted primarily
from the net proceeds of $1.1 million from a March 2006 private placement.

Net cash provided by operating activities

Operating cash flow for the nine months ended September 30, 2006 was $800,000 versus cash used of $974,000 in the comparable period in 2005. Net loss
of $647,000 and a reduction of $542,000 of deferred revenue were the main uses of cash while non cash charges of $778,000 and a reduction in accounts receivable of $255,000 were the main sources of cash for the nine months ended September 30,
2006. The reduction in deferred revenue was primarily attributable to the recognition of revenue on a consulting contract as well as reduced deferred revenue for service obligations. The reduction in accounts receivable relates to reduced payment
terms and improved collections. Net loss of $1,309,000 was the main use of cash in the nine months ended September 30, 2005.

Net
cash used by investing activities

Net cash used by investing increased in the nine months ended September 30, 2006 as a result of
purchases of software and computer equipment for internal and sales demonstration use.

Net cash used by financing activities

Net cash used by financing activities in the nine months ended September 30, 2006 was a result of the pay-down of our bank debt of
$1.4 million offset by $1.1 million net cash provided in a March 2006 private placement.

We have a loan agreement with Silicon Valley Bank
SVB which provides for borrowing of up to $3.5 million based on the level of certain of our North American accounts receivable. We were in compliance with the covenant requiring us to maintain $(1,250,000) in minimum tangible net worth
as of September 30, 2006. Our tangible net worth was $847,000 at September 30, 2006.

At September 30, 2006, we had used
$641,000 of the facility with $1.5 million available but not used. The interest rate on the facility was 10.25% at September 30, 2006, computed as the SVB prime rate plus 2 percent. The loan is collateralized by substantially all of the assets
of the U.S. Corporation and requires maintenance of a minimum tangible net worth level. Other loan covenants include the need to maintain insurance on our property, monthly reporting to SVB, the need to obtain SVB approval for any extraordinary
action and a limitation on the U.S. corporations ability to transfer more than $600,000 to a foreign subsidiary.



19



---

##### Table of Contents

We collateralize various credit card and bank guarantees (used for customs clearance purposes) with cash
deposits at an international bank in the United Kingdom. This amounted to $168,000 at September 30, 2006.

Recent Accounting
Pronouncements

Our discussion and analysis of our financial condition and results of operations are based on our financial statements,
which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets,
liabilities and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate these estimates, including those related to revenue recognition, long-lived assets, and income taxes and stock-based
compensation. These estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for judgments about the carrying values of assets and
liabilities. Actual results may differ from these estimates under different assumptions or conditions. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that
are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimate that are reasonably likely to occur, could materially impact the consolidated financial
statements. We believe that the following update to our critical accounting policies reflect significant estimates and assumptions used in the preparation of the consolidated financial statements.

Stock-Based Compensation: In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial
Accounting Standards (SFAS) No. 123 (revised 2004), Share-Based Payment (SFAS No. 123 (R)). SFAS No. 123 (R) replaces SFAS No. 123, Accounting for Stock-Based Compensation,
supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees (APB No. 25), and amends SFAS No. 95, Statement of Cash Flows. SFAS No. 123 (R) requires entities to recognize
compensation expense for all share-based payments to employees and directors, including grants of employee stock options, based on the grant-date fair value of those share-based payments, adjusted for expected forfeitures.

Subsequent to our fiscal year ending December 31, 2005, we include SFAS 123R as a critical accounting policy. During the first quarter of fiscal
2006, the we adopted the provisions of, and account for stock-based compensation in accordance with, the Financial Accounting Standards Boards (FASB) Statement of Financial Accounting Standards No. 123revised 2004
(SFAS 123R), Share-Based Payment which replaced Statement of Financial Accounting Standards No. 123 (SFAS 123), Accounting for Stock-Based Compensation and supersedes APB Opinion No. 25
(APB 25), Accounting for Stock Issued to Employees. Under the fair value recognition provisions of this statement, stock-based compensation cost is measured at the grant date based on the fair value of the award and is
recognized as expense on a ratable basis over the requisite service period, which is the vesting period. We elected the modified-prospective method, under which prior periods are not revised for comparative purposes. The valuation provisions of SFAS
123R apply to new grants and to grants that were outstanding as of the effective date and are subsequently modified. Estimated compensation for grants that were outstanding as of the effective date will be recognized over the remaining service
period using the compensation cost estimated in the prior SFAS 123 pro forma disclosures.

The adoption of SFAS 123R had a material impact
on our consolidated financial position, results of operations and cash flows. See Note 5 to the financial statements for further information regarding our stock-based compensation assumptions and expenses, including pro- forma disclosures for prior
periods as if we had recorded stock-based compensation expense during these periods.

Item 3. Quantitative and Qualitative Disclosures about Market Risk Derivatives and Financial Instruments

Foreign Currency Fluctuations

In the normal course of business, we are exposed to market risk from
the effect of foreign exchange rate fluctuations on the U.S. dollar value from our foreign operations. Our revenues are primarily denominated in U.S. dollars, sterling and euros. In addition, the operating expenses incurred by our foreign
subsidiaries are denominated in local currencies. Accordingly, we are subject to exposure from movements in foreign currency exchange rates. To date, the effect of changes in foreign currency exchange rates have impacted our financial position
and operating results. We currently do not use financial instruments to hedge foreign currency risks.



20



---

##### Table of Contents

Interest Rate Risk

For the nine months ended September 30, 2006, there were no material changes from the disclosures made in our Form 10-K for the year ended December 31, 2005. We maintain our funds as cash or cash
equivalents, primarily in money market investments with a maturity of less than 90 days. These funds were invested at an average interest rate of 5.1% during the third quarter of 2006. These investments are not subject to interest rate risk.

Item 4. Controls and Procedures

(a)Evaluation of disclosure controls and procedures. Based on an
evaluation as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 (the Exchange Act) were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time
periods specified in Securities and Exchange Commission rules and forms.

(b) Changes in internal control over financial reporting.There has been no change in our internal control over financial reporting during the quarter ended September 30, 2006 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any other material legal proceedings.

Item 1A. Risk Factors

The following represent some of the factors that create risk and uncertainty for
our business and us. If any of the following factors actually occur, our business, financial condition or results of operations could be materially adversely affected.

The fact that there is a merger pending could have an adverse effect on our business, revenue and results of operations.

While our proposed merger with Genetix is pending, it creates uncertainty about our future. As a result of this uncertainty, customers and other business partners may decide to delay, defer, or cancel purchases of our products or other
business with us pending completion of the merger or termination of the merger agreement.

In addition, while the merger is pending, we are subject to a
number of risks, including:



| |  | the diversion of management and employee attention and the unavoidable disruption to our relationships with customers and other partners may detract from our ability to grow
revenues and achieve our corporate objectives;
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | the loss of employees who may depart due to their concern about losing their jobs following the merger;
| | - | -------------------------------------------------------------------------------------------------------



| |  | we have and will continue to incur significant expenses related to the merger prior to its closing; and
| | - | -------------------------------------------------------------------------------------------------------



| |  | we may be unable to respond effectively to competitive pressures, industry developments and future opportunities.
| | - | -----------------------------------------------------------------------------------------------------------------

These risks may adversely affect our business, revenue and results of operations.

We have incurred substantial expenses in connection with the proposed merger with Genetix. If the proposed merger with Genetix is not completed, we will still be required to pay those expenses and we may be required to pay a significant
termination fee, both of which may substantially impair our cash balances.

The proposed merger with Genetix is subject to certain
closing conditions, including the approval of our stockholders. There are no assurances that we will obtain such approval. In this regard, one of our significant stockholders holding 16.1% of our shares has publicly announced that it will vote
against the merger announced on August 31 at $3.06 per share. If the merger were not to be completed, we may be required to pay Genetix a termination fee of up to $1,040,000 and we will be required to pay the substantial expenses that we have
incurred in connection with the proposed merger. By way of example, if our stockholders fail to approve the merger, we will be required to pay Genetix $200,000. Alternatively, if this merger were not completed because we receive a proposal from a
third party superior to Genetixs transaction and we change our recommendation to our stockholders, or because we do not hold a stockholders meeting to approve the merger by January 15, 2007, and we enter into a definitive agreement for a
transaction superior to Genetixs by January 14, 2008, we will be



21



---

##### Table of Contents

required to pay Genetix $1,040,000. To date, we have incurred $350,000 in fees related to the issuance of two fairness
opinions and expect to incur approximately $295,000 in legal fees, and approximately $150,000 in proxy related costs. In addition, we have accrued approximately $500,000 in expenses for the retention of employees, these expenses would be borne by us
should our shareholders vote against the proposed merger. As of September 30, 2006, we had cash on hand of approximately $3.4 million. The payment of a termination fee and our payment of already incurred expenses without completing the proposed
merger may substantially impair our cash balances.

We have a history of operating losses and may never achieve profitability.

We have not been profitable on a fiscal year basis since our inception in 1986. We incurred net losses of $1.0 million and $3.3 million
in 2005 and 2004, respectively. As of September 30, 2006, we had an accumulated deficit of $51.0 million. We will continue to incur significant costs as we continue our efforts to develop and market our current systems and related applications.
If we do achieve profitability in any period, we may not be able to sustain or increase our profitability on a quarterly or annual basis.

The detection, quantification and characterization of tumor cells in circulating blood involve complex and unproven technologies. Our CTC initiative may never become commercially successful.

We are developing a system for the detection, quantification and characterization of tumor cells in circulating blood. Some of the technologies involved
are complex and unproven. The timing of the systems development may not meet our expectations. It is possible that we may never be successful in developing a system. Successful development of a system will require us to optimize a protocol for
the enrichment of tumor cells. Optimizing a protocol for the enrichment of tumor cells is an effort that entails adapting existing research technology for a clinical setting, a challenging effort that neither we nor our competitors have yet
succeeded in accomplishing. We may have to partner with one or more parties in our efforts to develop and optimize the system. Such partnerships may not be on terms favorable to us. Even if we were successful in developing a system, we may not have
sufficient resources to commercialize the system. We may have to engage one or more commercialization partners and such relationships may not result in returns adequate to justify our investment. The market for a diagnostic test based on circulating
tumor cells may never develop. Despite significant investment and a distribution partnership with Veridex, a Johnson and Johnson Inc. subsidiary, the one company that has a commercial product in this market has generated marginal revenue to date.

Our common stock is currently traded on the over-the-counter market, and the liquidity of our stock may be seriously limited.

We have been delisted from the Nasdaq Capital Market. Our common stock is currently traded on the over-the-counter bulletin board.
Trading on the over-the-counter bulletin board may adversely impact our stock price and liquidity, and the ability of our stockholders to purchase and sell our shares in an orderly manner. Furthermore, the delisting of our shares could damage our
general business reputation and impair our ability to raise additional funds.

We expect quarterly revenue and operating results to vary
significantly in future periods, which could cause our stock price to fluctuate. If our operating results are below expectations, our stock price could drop.

We have experienced significant fluctuations in our quarterly operating results, and we expect to continue to experience fluctuations in the future. Our customers, who are primarily public and private clinical
laboratories, research organizations and hospitals, generally operate on annual budgets. Their budgeting cycles and spending practices affect our revenues. Factors that may have an influence on our operating results in any particular quarter
include:



| |  | demand for our products,
| | - | ------------------------



| |  | seasonality of our sales,
| | - | -------------------------



| |  | accounting, tax, consulting and other professional fees,
| | - | --------------------------------------------------------



| |  | new product introductions by us or our competitors, and the costs and time required for a transition to the new products,
| | - | -------------------------------------------------------------------------------------------------------------------------



| |  | delays in the timing of introduction of new products, systems or applications due to longer research and development cycles than anticipated,
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------



| |  | changes in the amount of reimbursement to our customers by insurance companies and other third parties for tests conducted on our systems,
| | - | ------------------------------------------------------------------------------------------------------------------------------------------



22



---

##### Table of Contents

| |  | timing of orders and shipments for capital equipment sales,
| | - | -----------------------------------------------------------



| |  | our mix of sales between our distributors and our direct sales force,
| | - | ---------------------------------------------------------------------



| |  | competition, including pricing pressures,
| | - | -----------------------------------------



| |  | timing and amount of research and development expenses, including clinical and pre-clinical trial-related expenditures,
| | - | -----------------------------------------------------------------------------------------------------------------------



| |  | foreign currency fluctuations, and
| | - | ----------------------------------



| |  | delays between our incurrence of expenses to develop new products, including expenses related to marketing and service capabilities, and the timing of sales and payments received
for the new products.
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In addition, because we develop applications for our imaging systems, a delay in the release of a
system would result in the delay of applications for the system.

It is possible in the future that our operating results will be below the
expectations of public market analysts and investors. If our operating results fall below market expectations, the price of our common stock could drop significantly.

Our operating and capital expenditures are difficult to predict and can depend on a number of factors that are not entirely within our control.

The exact timing and amount of our operating and capital spending cannot be accurately determined and will depend on several factors, including:



| |  | market acceptance and demand for our products,
| | - | ----------------------------------------------



| |  | competing technological and market developments,
| | - | ------------------------------------------------



| |  | progress of our research and development efforts and planned clinical investigations, and
| | - | -----------------------------------------------------------------------------------------



| |  | commercialization of products currently under development by us and our competitors.
| | - | ------------------------------------------------------------------------------------

We have expended and will continue to expend substantial amounts of money for research and development, preclinical testing, clinical investigations, working capital needs and manufacturing and marketing of our
products. Our future research and development efforts, in particular, are expected to include development of additional applications for our current cytogenetic and OncoPath systems, as well as a system to detect circulating tumor cells which will likely require additional funds.

Our internal controls and procedures for financial reporting may not ensure that our public filings include timely and reliable financial
information.

The effectiveness of our controls and procedures is limited by a variety of factors including:



| |  | faulty human judgment and simple error, omissions or mistakes,
| | - | --------------------------------------------------------------



| |  | fraudulent action of an individual or collusion of two or more people,
| | - | ----------------------------------------------------------------------



| |  | inappropriate management override of procedures, and
| | - | ----------------------------------------------------



| |  | the possibility that our enhanced controls and procedures may still not be adequate to assure timely and accurate information.
| | - | ------------------------------------------------------------------------------------------------------------------------------

If we fail to maintain effective internal controls and procedures for financial reporting in place, we could be unable to provide timely and accurate
financial information, be subject to, civil and criminal sanctions. By way of example, in March 2005, as a result of an internal investigation by our Audit Committee, we restated our consolidated financial statements for the years ended
December 31, 2003 and 2002 and for the quarters ended March 31, 2004 and September 30, 2004 to reflect adjustments to our previously reported financial information. Also, as a result of the investigation, we were unable to timely file
the Form 10-Q for the quarter ended September 30, 2004 or to announce our financial results for that period.



23



---

##### Table of Contents

The marketing and sale of our products requires regulatory approval and on-going certifications.
Failure to obtain and maintain required regulatory approvals and certifications could prevent or delay our ability to market and sell our products and may subject us to significant regulatory fines or penalties.

The FDA regulates design, testing, manufacturing, labeling, distribution, marketing, sales and service of our products. Our products are marketed in the
United States according to premarket notifications to the FDA under Section 510(k) of the Food, Drug and Cosmetic Act.

Unless an
exemption applies, each medical device that we wish to market in the United States must first receive either 510(k) clearance or premarket approval from the FDA. The FDAs 510(k) clearance process usually takes from three to twelve months, but
may take longer. The premarket approval process generally takes from one to three years from the time FDA files the application, but it can be significantly longer and can be significantly more expensive. Although we have obtained the necessary
510(k) clearance for our products, our 510(k) clearance can be revoked if safety or effectiveness problems develop.

We may need to seek
additional regulatory approval for clearances if we modify existing products or intend to market other products under development and cannot be certain that we would obtain 510(k) clearance or premarket approval in a timely manner or at all. If the
FDA requires us to seek 510(k) clearance or premarket approval for any modification to a previously cleared product, we also may be required to cease marketing or recall the modified device until we obtain such clearance or approval. Delays in
obtaining clearances or approvals will adversely affect our ability to market and sell our products and may subject us to significant regulatory fines or penalties, which would result in a decline in revenue and profitability. We have in the past
received, and may in the future receive, warning letters from the FDA related to improper promotion of an unapproved use of our products. As a result of such warning letters, the FDA could request that we modify our promotional materials or could
subject us to regulatory enforcement actions, including injunction, seizure, civil fine and criminal penalty.

Intellectual property
litigation, can be costly, lead to payment of substantial damages or royalties and/or prevent us from manufacturing and selling our current and future products.

The medical diagnostic equipment industry, in general, is extremely competitive. Litigation among the participants regarding patent and other intellectual property rights is common. For example, in February 2004, we
were sued by Clarient, Inc. The lawsuit claimed that our Ariol system infringed on three Clarient patents. Clarient sought damages, as well as an injunction barring us from, among other things, making, using, or selling any device in the United
States that used Clarients patents-in-suit. The case settled in March 2005. Whether or not intellectual property infringement claims have merit, they are time consuming and expensive to litigate and divert the attention of technical and
management personnel from other work. We may be involved in other litigation to defend against claims of infringement, to enforce our patent rights or to protect our trade secrets. If any other partys claims are upheld in any litigation or
administrative proceeding, we could be prevented from exploiting the subject matter of those claims or forced to obtain licenses from the patent owners or to redesign our products or processes to avoid infringement. In the event of any infringement
by us, we cannot assure you that we will be able to successfully redesign our products or processes to avoid infringement. Accordingly, an adverse determination in a judicial or administrative proceeding or failure to obtain necessary licenses could
prevent us from manufacturing and selling our products and could require us to pay substantial damages and/or royalties and/or prevent us from manufacturing and selling our current and future products.

Our success depends, in part, on our ability to protect our intellectual property rights. We could lose sales and our competitive advantage could be
harmed if we are not able to prevent infringement of our intellectual property rights.

We rely primarily on trade secret protection and
on our unpatented proprietary know-how in the development and manufacturing of our products. Our trade secrets or proprietary technology could become known or be independently developed by our competitors. In addition, the patents we hold may not be
sufficiently broad to protect what we believe to be our proprietary rights. Our issued patents could also be disallowed, challenged or circumvented by our competitors.

We cannot assure you that competitors or other parties have not filed or in the future will not file applications for, or have not received or in the future will not receive, patents or obtain additional proprietary
rights relating to products or processes used or proposed to be used by us. In that case, our competitive position could be harmed and we may be required to obtain licenses to patents or proprietary rights of others.

The market for medical diagnostic equipment for cancer, prenatal and other genetic tests is extremely competitive. Our competitors may succeed in
developing products and obtaining related regulatory approvals faster than us.

The medical diagnostic equipment industry is highly
competitive and competition is likely to intensify. Certain of our competitors have greater financial and technical resources and production and marketing capabilities than us. We cannot



24



---

##### Table of Contents

assure you that these competitors will not succeed in developing technologies and products that are more effective,
easier to use or less expensive than those which are currently offered or being developed by us or that would render our technology and products obsolete and noncompetitive. In addition, some of our competitors have significantly greater experience
than we have in conducting clinical investigations of new diagnostic products and in obtaining FDA and other regulatory clearances and approvals of products. Accordingly, our competitors may succeed in developing and obtaining regulatory approvals
for such products more rapidly than us.

We operate in a consolidating industry which creates barriers to our market penetration.

The healthcare industry in recent years has been characterized by consolidation. Large hospital chains and groups of affiliated
hospitals prefer to negotiate comprehensive supply contracts for all of their supply needs at once. Large suppliers can often equip an entire laboratory and offer these hospital chains and groups one-stop shopping for laboratory
instruments, supplies and services. Larger suppliers also typically offer annual rebates to their customers based on the customers total volume of business with the supplier. The convenience and rebates offered by these larger suppliers are
administrative and financial incentives that we do not offer our customers. The success of our future plans will depend in part on our ability to overcome these and any new barriers resulting from continued consolidation in the healthcare industry.

Any disruption or delay in the supply of components or custom subassemblies could require us to redesign our products or otherwise
delay our ability to assemble our products, which could cause our sales to decline and result in continued net losses.

We assemble our
products from a combination of (i) commodity technology components, such as computers and monitors, (ii) custom subassemblies, such as automated filter wheels, (iii) proprietary hardware for scanning microscopy and (iv) operating
systems and proprietary applications software. While we typically use components and subassemblies that are available from alternate sources, any unanticipated interruption of the supply of these components or subassemblies could require us to
redesign our products or otherwise delay our ability to assemble our products, which could cause our sales to decline and result in continued net losses.

If we fail to comply with Quality System Regulations, our manufacturing operations could be delayed, and our product sales and profitability could suffer.

Our manufacturing processes and those of our suppliers are required to comply with the FDAs Quality System Regulation, or QSR, which covers the
procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products. The FDA enforces the QSR through inspections. We were subject to a QSR inspection in December
2001 and May 2003, as a result of which, the FDA made observations to which we responded. Following our response, the FDA informed us that it did not intend to take further action. We may be inspected in the future and we cannot assure you that we
would pass any future inspections. If we fail a QSR inspection, our operations could be disrupted and our manufacturing delayed. Failure to take adequate corrective action in response to a QSR inspection could force a shutdown of our manufacturing
operations and a recall of our products, which would cause our product sales and profitability to suffer.

The marketing and sale of our
products outside of the United States is subject to regulations, which vary from those in the United States. Failure to obtain and maintain required regulatory approvals could prevent or delay our ability to market and sell our products in
international markets.

The regulatory environment for testing, manufacturing, labeling, distributing, marketing and sale of our
products varies from country to country. Currently, some of our products, and modifications to these products, may be subject to pre-market approval in selected countries that are members of the European Union. Our products, and modifications to
these products, are also subject to other regulatory requirements in those and other countries. Our failure to comply with applicable regulatory requirements could result in fines, injunctions, civil penalties, suspensions or loss of regulatory
approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Our products have been classified in
Europe as In Vitro diagnostic devices (IVDs), which are regulated under a different standard than medical devices. As such, our products are subject to the requirements of the In Vitro Diagnostic Medical Device Directive (IVDD).
An IVD is defined as a device which is a reagent, reagent product, kit, instrument, equipment or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of samples derived from the human
body with a view to providing information on a physiological state, state of health or disease, or congenital abnormality. IVDs are specifically excluded from the provisions of the Medical Device Directive (MDD), although IVDs are
subject to equally stringent but different controls under the IVDD and other directives. If it is determined that our products are marketed as or intended to be issued as equipment that can produce therapeutic effects or alleviate the symptoms of
any disability, injury or illness, the equipment may then fall within the scope



25



---

##### Table of Contents

of the MDD and product registration and appropriate documentation, including possible clinical trials would be required
prior to commercialization. That same medical equipment, if also intended and promoted by us for use in the examination of samples derived from the human body with a view to providing information on a physiological state, state of health or disease,
or congenital, abnormality, would also be regulated under the IVDD, requiring performance data, including where appropriate, analytical sensitivity, diagnostic sensitivity, analytical specificity, diagnostic specificity, accuracy, repeatability and
reproducibility.

Although our products are currently regulated under the IVDD, European regulatory authorities may independently interpret
our marketing and promotional claims as falling within the scope of the MDD, and require us to comply with its differing requirements, including substantiating any therapeutic claims. A redefinition could harm our marketing and sales if we were
restricted from marketing or selling our products until we are able to comply with the MDD. Moreover, a member state of the EU or any other European country could adopt other laws or regulations that require approval to market and sell our products.

We depend on distributors to sell our products outside of North America. Sales through our distributors may be lower than direct sales
efforts.

We rely substantially on independent distributors and sales agents to market and sell our products outside of North America.
We cannot assure you that distributors and agents will devote adequate resources to support sales of our products.

Our international
sales and operations are a significant portion of our business. Changes in international markets and currency fluctuations could lead to a decline in our revenues or result in continued net losses.

We have significant international operations based in the United Kingdom. As of September 30, 2006, 27 employees, constituting approximately 42% of
the total number of our employees, were based outside the United States. We generate a substantial portion of our revenues from outside of the United States. In 2005 and 2004, we derived approximately 35% and 45% of our total revenues, respectively,
from our customers and distributors outside of North America. We expect that international sales will continue to account for a significant portion of our revenues.

The international nature of our business subjects us and our representatives, agents and distributors to laws and regulations of the jurisdictions in which we operate and sell our products. Changes in overseas
economic conditions, currency exchange rates, foreign tax laws or tariffs or other trade regulations could have an adverse effect on our financial condition or results of operations. For example, most of our international sales are denominated in
U.S. dollars, U.K. pounds sterling or Euros. We do not attempt to reduce the risk of currency fluctuations by hedging. Currency fluctuations against the U.S. dollar could substantially reduce our U.S. dollar revenue or increase our costs. Changes in
currency exchange rates could also make the products of our competitors less expensive than ours, which could result in our customers purchasing our competitors products instead of ours.

Export controls could prevent us from exporting our products to foreign countries or customers, which could cause our sales to decline and result in
continued net losses.

Our research, investigational and clinical products are subject to regulation by U.S. Department of Commerce
export controls, primarily as they relate to the associated computers. These controls could prevent us from exporting our products to certain countries or customers, which could cause our sales to decline and result in continued net losses.

Our customers rely substantially on the availability of third-party reimbursement. Our customers failure to obtain sufficient
reimbursement from third-party payors could cause our sales and the future growth of our business to decline.

Hospitals, physicians and
other health care providers in the United States that purchase our products generally rely on third-party payors and other sources for reimbursement of health care costs to reimburse all or part of the cost of the procedures in which our products
are used. If hospitals, physicians and other health care providers are unable to obtain adequate reimbursement from third-party payors for the procedures in which our products or products currently under development are intended to be used, our
sales and future growth of our business could be adversely affected.

Market acceptance of our products and products under development in
countries outside of the United States is also dependent on availability of reimbursement within prevailing health care payment systems in those countries. Reimbursement and health care payment systems in international markets vary significantly by
country, and include both government-sponsored health care and private insurance. We cannot assure you that we will be able to obtain international reimbursement approvals in a timely manner, if at all. Failure to receive international reimbursement
approvals could harm the market acceptance of our products in the international markets in which such approvals are sought.



26



---

##### Table of Contents

We depend on key technical, scientific and management personnel. Any difficulty in retaining our
current employees or in hiring new employees could harm our ability to maintain and build our business operations.

Our future success
depends in significant part upon the continued service of key scientific, technical and management personnel, and our continuing ability to attract and retain them. Competition for these personnel is intense and we cannot assure you that we can
retain our key scientific, technical and managerial personnel or that we can attract or retain other highly qualified scientific, technical and managerial personnel in the future. Our key employees include Robin Stracey, our President and Chief
Executive Officer, Terence Griffin, our Chief Financial Officer, and Diane Day, our Corporate Vice President-Regulatory, Quality and Clinical Affairs.

We have taken steps to retain our key employees, including the granting of stock options that vest over time, and we have entered into employment agreements with key employees. The loss of key personnel, especially if
without advance notice, or the inability to hire or retain qualified personnel, could harm our ability to maintain and build our business operations. Furthermore, we have no key man life insurance on any of our key employees.

In addition, some companies have adopted a strategy of suing or threatening to sue former employees and their new employers to discourage those employees
from leaving. As we hire new employees from our current or potential competitors, we may become a party to one or more lawsuits involving our employees. Any future litigation against us or our employees, regardless of the merit or outcome, may
result in substantial costs and expenses to us and may divert managements attention away from the operation of our business.

Undetected errors or failures in our software could result in loss or delay in the market acceptance for our product, lost sales or costly litigation.

Our existing products and products under development involve one or more software components that facilitate the detection of chromosomal, genetic or protein abnormalities through the interaction of certain imaging
algorithms with the sample under examination. This software, including any new versions that may be released, may contain undetected errors or failures. We cannot assure you that, despite testing by us and our customers, all errors will be found in
the software components of our products. Errors in our software could result in loss or delay in the market acceptance for our products, lost sales or costly litigation.



27



---

##### Table of Contents

A successful products liability claim brought in excess of our insurance coverage could require us to
pay substantial damages and result in harm to our business reputation.

The manufacture and sale of our products involve the risk of
product liability claims. We cannot assure you that the coverage limits of our insurance policies will be adequate in the event we are successfully sued. We evaluate our coverage limits on a regular basis and in connection with the introduction of
products currently under development. However, liability insurance is expensive and may not be available on commercially reasonably terms, if at all, or in sufficient coverage amounts to cover all eventualities. A successful claim brought against us
in excess of our insurance coverage could require us to pay substantial damages and result in harm to our business reputation.

A small
number of our stockholders, together with our officers and directors have substantial control over our stock and could delay or prevent a change in corporate control.

Five of our stockholders who are institutions beneficially own over 56.5% of our outstanding common stock. Officers and directors as a group beneficially own 5.1% of our stock as of October 15, 2006. These
stockholders will, to the extent they act together, have the ability to exert significant influence and control over matters requiring the approval of our stockholders. Their interests may be different from yours. Matters that typically require
stockholder approval include: (i) election of directors; (ii) approval of a merger or consolidation; and (iii) approval of a sale of all or substantially all of our assets. Accordingly, you may not be able to influence any action we
take or consider taking, even if it requires a stockholder vote.

Our stock price has been volatile. It will likely be volatile in the
future. You could lose all or a portion of your investment.

The market prices for securities, generally, and for medical diagnostic
instrument companies, in particular, including our common stock, have historically been highly volatile. Investment in our common stock is risky, and you could lose all or part of your investment. Many factors could cause the market price of our
stock to fluctuate, perhaps substantially, including the announcement of:



| |  | an Audit Committee investigation,
| | - | ---------------------------------



| |  | our need to seek additional funding in the near future to maintain our operations as planned,
| | - | ---------------------------------------------------------------------------------------------



| |  | material weakness in our internal controls or procedures,
| | - | ---------------------------------------------------------



| |  | technological innovations or new competitor products,
| | - | -----------------------------------------------------



| |  | developments concerning proprietary rights, including patents and litigation matters,
| | - | -------------------------------------------------------------------------------------



| |  | publicity regarding actual or potential results with respect to products under development,
| | - | -------------------------------------------------------------------------------------------



| |  | regulatory developments in the United States or other countries,
| | - | ----------------------------------------------------------------



| |  | changes or potential changes in reimbursement rates to our customers,
| | - | ---------------------------------------------------------------------



| |  | developments in relationships with partners or distributors,
| | - | ------------------------------------------------------------



| |  | public concern as to the safety of new technologies, or
| | - | -------------------------------------------------------



| |  | changes in financial estimates by securities analysts or our failure to meet those estimates,
| | - | ---------------------------------------------------------------------------------------------

In addition, changes in our operating results may cause the market price of our common stock to fluctuate.

Any future sale of a substantial number of shares eligible for resale could depress the trading price of our stock, lower our value and make it more
difficult for us to raise capital.

According to Forms 4, 13D and 13G filed by our stockholders, approximately 3.1 million shares
of our common stock, stock options and warrants (representing approximately 66.8% of the total shares outstanding) are held by affiliates. Should anyone of our affiliates sell any or all of their holdings in our common stock, it may have the effect
of depressing the trading price of our common stock. In addition, such sales could lower our value and make it more difficult for us to raise capital.



28



---

##### Table of Contents

Our preferred shares rights plan, certificate of incorporation, bylaws and Delaware law contain
provisions that could prevent or delay a takeover of Applied Imaging and negatively impact shareholder value.

On May 28, 1998, we
adopted a preferred shares rights plan. The purpose of the plan is to assure fair value in the event of a future unsolicited business combination or similar transaction involving Applied Imaging. If an individual or entity accumulates or solicits a
tender or exchange offer for 20% of our common stock, or 25% in the case of Special Situation Funds and affiliates, the rights become exercisable for additional shares of our preferred stock. The intent of these rights is to encourage a potential
acquirer to negotiate with our Board of Directors to increase the consideration paid for our stock. The existence of this plan, however, may deter a potential acquirer, which could negatively impact stockholder value. We also are authorized to issue
6,000,000 shares of undesignated preferred stock, which we may issue without stockholder approval and upon such terms as our Board of Directors may determine.

In addition, our basic corporate documents and Delaware law contain provisions that might enable our management to resist a takeover. Any of these provisions might discourage, delay or prevent a change in the control
of Applied Imaging or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common
stock.

Changes in, or interpretations of, accounting principles, such as expensing of stock options, could result in unfavorable
accounting charges.

We prepare our consolidated financial statements in conformity with U.S. generally accepted accounting principles.
These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even
retroactively affect previously reported transactions. Our accounting principles that recently have been or may be affected by changes in the accounting principles are as follows:



| |  | software revenue recognition
| | - | ----------------------------



| |  | accounting for share-based payments
| | - | -----------------------------------



| |  | accounting for business combinations and related goodwill
| | - | ---------------------------------------------------------

In particular, the FASB recently issued SFAS 123R which requires the measurement of all share-based payments to employees, including grants of employee stock options, using a fair-value-based method and the recording of such expense in
our consolidated statements of income. The accounting provisions of SFAS 123R are effective for annual periods beginning after June 15, 2005. We adopted SFAS 123R in the first quarter of fiscal year 2006. We believe that the adoption
of SFAS 123R will have a significant adverse effect on our reported financial results and may impact the way in which we conduct our business. Please refer to the section titled Stock-based Compensation in the notes to the financial
statements.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Submission of Matters to a Vote of Security Holders

None.

ITEM 5. Other Information

None.

Item 6. Exhibits.

(a) Exhibits.



29



---

##### Table of Contents

|            |  |                                                                                                                                                
|----------- |  | -----------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                    
|2.1(1)      |  | Agreement and Plan of Merger dated August 31, 2006 by and among Genetix Group plc, Alpine Merger Corporation and Applied Imaging Corp.         
|            | 
|2.2(2)      |  | Amendment No. 1 to August 31, 2006 Merger Agreement dated October 20, 2006                                                                     
|            | 
|2.3(3)      |  | Amendment No. 2 to August 31, 2006 Merger Agreement dated October 27, 2006                                                                     
|            | 
|2.4(4)      |  | Amendment No. 3 to August 31, 2006 Merger Agreement dated November 2, 2006                                                                     
|            | 
|2.5(5)      |  | Amendment No. 4 to August 31, 2006 Merger Agreement dated November 9, 2006                                                                     
|            | 
|31.1        |  | Chief Executive Officers Certification Pursuant to 15 U.S.C. Section 7241                                                                     
|            | 
|31.2        |  | Chief Financial Officers Certification Pursuant to 15 U.S.C. Section 7241                                                                     
|            | 
|32.1        |  | Certificate of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|            | 
|32.2        |  | Certificate of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

---

|(1) | Filed as Exhibit 2.1 to Applied Imaging Corp.s Form 8-K dated September 1, 2006 and incorporated by reference herein.
|--- | ----------------------------------------------------------------------------------------------------------------------

|(2) | Filed as Exhibit 2.1 to Applied Imaging Corp.s Form 8-K dated October 24, 2006 and incorporated by reference herein.
|--- | ---------------------------------------------------------------------------------------------------------------------

|(3) | Filed as Exhibit 2.1 to Applied Imaging Corp.s Form 8-K dated October 31, 2006 and incorporated by reference herein.
|--- | ---------------------------------------------------------------------------------------------------------------------

|(4) | Filed as Exhibit 2.1 to Applied Imaging Corp.s Form 8-K dated November 3, 2006 and incorporated by reference herein.
|--- | ---------------------------------------------------------------------------------------------------------------------

|(5) | Filed as Exhibit 2.1 to Applied Imaging Corp.s Form 8-K dated November 13, 2006 and incorporated by reference herein.
|--- | ----------------------------------------------------------------------------------------------------------------------



30



---

##### Table of Contents

APPLIED IMAGING CORP.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.



|                        |  |  |  |                                    |  |                        
|----------------------- |  |  |  | ---------------------------------- |  | -----------------------
|                        |  |  |  | APPLIED IMAGING CORP. (Registrant)
|                        |  |  | 
|Date: November 13, 2006 |  |  |  | By:                                |  | /S/ ROBIN STRACEY      
|                        |  |  |  |                                    |  | Robin Stracey          
|                        |  |  |  |                                    |  | Chief Executive Officer



31